HRS 7535
Alternative Names: HRS-7535Latest Information Update: 08 Oct 2024
At a glance
- Originator Shandong Suncadia Medicine
- Developer Jiangsu Hengrui Medicine Co.; Shandong Suncadia Medicine
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 01 Oct 2024 Shandong Suncadia Medicine plans a phase I/II trial for Obesity in China (PO, Tablet) (NCT06621316)
- 18 Sep 2024 Shandong Suncadia Medicine plans the phase III OUTSTAND-2 trial for Type 2 diabetes mellitus (In adults, In the elderly) in China (PO) in September 2024 (NCT06589765)
- 18 Jul 2024 Shandong Suncadia Medicine plans a phase I trial for Type 2 diabetes mellitus (In Volunteers) in China (PO) in July 2024 (NCT06495931)